Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK 2,260.00
+16.00 (0.71%)
Sep 18, 2026, 4:59 PM CET
Genmab Market Cap
Genmab has a market cap or net worth of 135.04 billion as of September 18, 2026. Its market cap has increased by 24.02% in one year.
Market Cap
135.04B
Enterprise Value
159.67B
Revenue
27.03B
Ranking
n/a
PE Ratio
27.30
Stock Price
2,260.00
ChartMarket Cap Chart
Since October 18, 2000, Genmab's market cap has increased from 3.68B to 135.04B, an increase of 3,565.50%. That is a compound annual growth rate of 14.90%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 18, 2026 | 135.04B | 8.16% |
| Dec 30, 2025 | 124.86B | 31.70% |
| Dec 30, 2024 | 94.81B | -32.65% |
| Dec 29, 2023 | 140.77B | -26.77% |
| Dec 30, 2022 | 192.23B | 11.72% |
| Dec 30, 2021 | 172.06B | 6.80% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Novo Nordisk | 1.25T |
| Coloplast | 94.37B |
| Demant | 63.48B |
| ALK-Abelló | 44.04B |
| H. Lundbeck | 41.63B |
| Zealand Pharma | 19.27B |
| Ambu A/S | 17.10B |
| Bavarian Nordic | 15.70B |